Exagen

Exagen Inc. is a patient-focused, discovery-driven commercial-stage life sciences company that aids patients and healthcare providers in the diagnosis, prognosis, and management of autoimmune conditions. The company describes itself as dedicated to transforming the care continuum for patients suffering from debilitating chronic autoimmune diseases, with a portfolio of innovative products that enable timely differential diagnosis, prognosis, management, and optimization of therapeutic intervention. Its mission is to provide clarity in autoimmune disease decision making with the goal of improving patients' clinical outcomes. Exagen's core offering is the AVISE testing product line, which the company describes as next-generation insight to aid the treatment of autoimmune conditions. The AVISE portfolio includes diagnostic, prognostic, and monitoring tests. Diagnostic tests include AVISE CTD, a comprehensive tool powered by CB-CAPs technology designed to help distinguish patients with connective tissue disease or similar diseases with overlapping symptoms; AVISE Lupus, a 10-marker diagnostic test containing CB-CAPs and SLE-associated markers; AVISE APS for antiphospholipid syndrome; and AVISE Vasculitis AAV. Prognostic tests include AVISE SLE Prognostic, developed as an add-on to AVISE CTD to assess potential risk for organ involvement through thrombosis, cardiovascular events, lupus nephritis, and neuropsychiatric lupus, as well as a specialized test to identify rheumatoid arthritis patients at increased risk for joint damage. Monitoring tests include AVISE SLE Monitor, which leverages Erythrocyte-Bound C4d (EC4d) to assess patients with SLE, and therapeutic drug monitoring tests such as AVISE MTX for methotrexate polyglutamates and AVISE HCQ for hydroxychloroquine in whole blood. The company operates a clinical laboratory and serves physicians and patients in the United States. During the COVID-19 pandemic, Exagen stated that its laboratory remained fully functional and that it addressed the needs of patients with its diagnostics, prognostics, monitoring, and at-home self-administered anti-TNF therapeutic. Exagen is publicly traded on the NASDAQ under the ticker XGN. John Aballi has served as President and CEO since October 2022, succeeding Ron Rocca, who was President and CEO at the time of the company's COVID-19 update. The company is headquartered in San Diego, California.

Exagen Inc. is a commercial-stage life sciences company focused on autoimmune disease testing. The company describes itself as patient-focused and discovery-driven, aiding patients and healthcare providers in the diagnosis, prognosis, and management of autoimmune conditions. Its relentless pursuit for laboratory excellence has enabled it to develop next-generation autoimmune testing to help empower physicians and improve patients' lives. Exagen's AVISE product line encompasses diagnostic, prognostic, and monitoring tests. The AVISE CTD test is a comprehensive diagnostic tool powered by CB-CAPs technology, designed to help distinguish patients with connective tissue disease or similar diseases with overlapping symptoms. AVISE Lupus is a 10-marker diagnostic test containing CB-CAPs and SLE-associated markers designed to aid in a timely differential diagnosis of SLE. AVISE APS is a specialized test to aid in the diagnosis and management of patients with antiphospholipid syndrome. AVISE Vasculitis AAV is an advanced diagnostic test specifically designed to aid in the differential diagnosis of ANCA-associated vasculitis. Prognostic tests include AVISE SLE Prognostic, developed as an add-on test to AVISE CTD to help assess a patient's potential risk for organ involvement through thrombosis, cardiovascular events, lupus nephritis, and neuropsychiatric lupus, and a specialized lab test to help identify rheumatoid arthritis patients with an increased risk for joint damage. Monitoring tests include AVISE SLE Monitor, which leverages Erythrocyte-Bound C4d (EC4d) to help assess patients with SLE, and therapeutic drug monitoring tests such as AVISE MTX for methotrexate polyglutamates and AVISE HCQ for hydroxychloroquine in whole blood. During the COVID-19 pandemic, Exagen stated that its laboratory remained fully functional and that it addressed the needs of patients with its diagnostics, prognostics, monitoring, and at-home self-administered anti-TNF therapeutic. Ron Rocca was President and CEO at that time. John Aballi has served as President and CEO since October 2022. He most recently served as SVP, GM, Urology and CLIA COO for Veracyte, a San Francisco-based molecular diagnostic company. In this role, he maintained P&L responsibility for the business unit, ultimately expanding the urology franchise to $120 million-plus in annual revenue while maintaining responsibility for the company's market access, billing and customer service functions in addition to Veracyte's four US-based CLIA laboratories. Prior to this role, Mr. Aballi was a key member of the leadership team which transformed Decipher Biosciences to the market leader in genomic testing for prostate cancer. Decipher Biosciences was sold to Veracyte in March 2021 for $600 million and Mr. Aballi served as the SVP & Chief Operating Officer at the company, responsible for all aspects of operations including sales, quality management, medical operations, customer service, software development, assay development, billing, managed care, and laboratory operations; he assumed this role in August 2018. Mr. Aballi previously served as the Head of Operations at Molecular Stethoscope, a company developing cell-free RNA based diagnostics, from September 2015 to August 2018. Prior to joining Molecular Stethoscope, Mr. Aballi served in various senior roles at Genoptix from January 2007 to September 2015. Mr. Aballi was a Board Member of PFS Genomics in San Diego, a molecular diagnostic company specializing in proprietary signature development in breast cancer, which was acquired by Exact Sciences in 2021. He holds an MBA from California Baptist University and dual degrees from UC San Diego in biochemistry and cell biology and economics. Jeff Black serves as Chief Financial Officer. Exagen is publicly traded on the NASDAQ under the ticker XGN.

• John Aballi appointed President & CEO

• Ron Rocca served as President and CEO during COVID-19 pandemic

Patient-focused, discovery-driven commercial-stage life sciences company providing clarity in autoimmune disease decision making.

• AVISE CTD

  Comprehensive diagnostic tool powered by CB-CAPs technology designed to help distinguish patients with connective tissue disease or similar diseases with overlapping symptoms.

• AVISE Lupus

  A 10-marker diagnostic test containing CB-CAPs and SLE-associated markers designed to aid in a timely differential diagnosis of SLE.

• AVISE SLE Monitor

  Advanced blood test that provides important information including proprietary EC4d level to assist physicians any time they assess the condition of a patient with SLE.

• AVISE SLE Prognostic

  Developed as an add-on test to AVISE CTD, helps assess a patient's potential risk for organ involvement through Thrombosis, Cardiovascular events, Lupus Nephritis and Neuropsychiatric Lupus.

• AVISE APS

  Specialized test to aid in the diagnosis and management of patients with antiphospholipid syndrome (APS).

• AVISE MTX

  Therapeutic drug monitoring of methotrexate polyglutamates.

• AVISE HCQ

  Therapeutic drug monitoring of hydroxychloroquine in whole blood.

• AVISE Vasculitis AAV

  The advanced diagnostic test specifically designed to aid in the differential diagnosis of AAV.

• AVISE Anti-CarP

  Specialized lab test to help identify rheumatoid arthritis (RA) patients with an increased risk for joint damage.

1. 1Exagen Inc. - Autoimmune Disease Testing Lab - Rheumatology Labexagen.com
2. 2Our Tests – Exagen Inc.exagen.com
3. 3Autoimmune Disease Testing Lab - Life Sciences Company - Exagen Inc.exagen.com
4. 4Leadership – Exagen Inc.exagen.com
5. 5Exagen Inc. - Wikidatawikidata.org